Latest profit margin for Evofem Biosciences: -163.56% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
Evofem Biosciences (EVFM) currently reports a profit margin of -163.56% as of June 2026. That compares with -37.98% in the prior-year period — down 330.7% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Evofem Biosciences's profit margin history and peer comparisons.
Evofem Biosciences's profit margin decreased from -37.98% to -163.56% — a 330.7% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Evofem Biosciences's profit margin of -163.56% is lower than the Healthcare sector average of 13.89%. That is roughly 1277.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' profit margin, but Evofem Biosciences's current -163.56% should be judged against Healthcare norms (sector average: 13.89%) and against EVFM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current profit margin of -163.56%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Evofem Biosciences, and consider following EVFM for alerts when major investors trade the stock.